| 발표일자: |
2016년 11월 4일(금) ~ 11월 6일(일) |
| 발표번호: |
P(e-poster)-055 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| 망막전막을 동반한 나이관련황반변성 환자에서의 유리체강내 항혈관내피세포성장인자 주입술의 치료효과 |
| 건양대학교 의과대학 김안과병원 안과학교실 명곡안연구소 |
| 김재민, 조한주, 김형석, 이동원, 김철구, 김종우 |
|
목적 : To evaluate the effect of epiretinal membranes (ERMs), detected with spectral-domain optical coherence tomography(SD-OCT), on the outcome of anti-vascular endothelial growth factor(VEGF) treatment for neovascular age-related macular degeneration(nAMD).
방법 : All patients were administered an initial series of three monthly loading injections of ranizumab or aflibercept, followed by further injections required. The visual and anatomical outcomes were compared between the eyes with ERMs and those without. Features of ERMs at baseline assessed with SD-OCT were evaluated and correlated with visual outcomes
결과 : Sixty-eight eyes(15.7%) with nAMD presented ERMs at baseline. The mean BCVA of these eyes, expressed as the logarithm of the minimum angle of resolution, improved from 0.75+-0.48(Snellen equivalent: 20/112) to 0.59+-0.44(20/77) after 12 months of treatment(P=0.021). Central foveal thickness also decreased from 381+-191um to 294+-167um(P<0.001). Cpmpared to the eyes without ERMs(366 eyes), the eyes with ERMs had a significantly thicker central fovea after treatment(P=0.020). However, the intergroup differences in BCVA improvement were not significant.
결론 : In eyes with nAMD, ERMs were infrequent. ERMs were not associated with visual outcome at baseline and after anti-VEGF treatment during 12-month follow up. Compared to the absence of ERMs, the presence of ERMs in eyes with nAMD did not affect visual outcome.
|
| |